Aamir Badruddin, MD
Neurocritical Care · Munster, INNPI 1871769331
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Janssen Research & Development, LLC at 28.8% of the total. 2025 is the largest year on record at $1,264, 4.7 times the $268 reported in 2019.
Across 50 payments — averaging $71.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1K
- Imperative Care, Inc$759
- Stryker$449
- Medtronic$444
- Penumbra, Inc.$329
- Microvention, Inc.$213
- plus $343 from 9 others
Across 78 payments — averaging $1953.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$97K
- Janssen Research & Development, LLC$54K
- Medical Device Business Services, Inc.$1K
What the payments were for
- Travel & lodging$1,49642%
- Food & beverage$2,04857%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 9 | $1,027 |
| Imperative Care, Inc | 5 | $759 |
| Stryker | 9 | $449 |
| Medtronic | 10 | $444 |
| Penumbra, Inc. | 3 | $329 |
| Microvention, Inc. | 3 | $213 |
| Balt USA, LLC | 1 | $140 |
| Microtransponder, Inc. | 1 | $33 |
| Chiesi USA, Inc. | 1 | $33 |
| Globus Medical | 2 | $29 |
| Cordis US CORP. | 2 | $27 |
| Johnson & Johnson | 1 | $23 |
| CSL Behring | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| AstraZeneca | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZOOM 88-T LARGE DISTAL PLATFORM$712
- Pipeline$213
- Micra$148
- Optima Coil System$140
- Penumbra System$129
- Penumbra Coil 400$128
- Sofia$123
- TREVO$119
- SURPASS EVOLVE$110
How this compares
Too few neurocritical care providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 12 | $66 |
| ClopidogrelClopidogrel Bisulfate | 18 | $35 |
Paid to pharmacies, not to this prescriber.
Other neurocritical care in Munster
- Farrukh ChaudhryMunster$3K
- Shamir HajiFort Wayne$6K
- Ruth TangonanFort Wayne$262
- Kevin BuiFort Wayne$42
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.